Azitra, Inc. (NYSEAMERICAN:AZTR) Sees Significant Growth in Short Interest

Azitra, Inc. (NYSEAMERICAN:AZTR) saw a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 435,300 shares, a growth of 247.1% from the May 31st total of 125,400 shares. Approximately 2.7% of the shares of the company are sold short. Based on an average trading volume of 1,880,000 shares, the short-interest ratio is currently 0.2 days.

Azitra Trading Down 30.2 %

NYSEAMERICAN:AZTR traded down $0.04 during trading hours on Friday, hitting $0.09. The company’s stock had a trading volume of 3,029,286 shares, compared to its average volume of 1,247,268. Azitra has a 52-week low of $0.09 and a 52-week high of $4.33. The company has a current ratio of 2.80, a quick ratio of 2.80 and a debt-to-equity ratio of 0.01.

Shares of Azitra are set to reverse split on Monday, July 1st. The 1-30 reverse split was announced on Monday, July 1st. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, July 1st.

Azitra (NYSEAMERICAN:AZTR) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.15) EPS for the quarter. Azitra had a negative return on equity of 237.52% and a negative net margin of 1,644.90%.

Azitra Company Profile

Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.